Analysis of gene polymorphism in hepatocellular carcinoma patients treated with sorafenib therapy
Not Applicable
Recruiting
- Conditions
- Heoatocellular carcinoma
- Registration Number
- JPRN-UMIN000016431
- Lead Sponsor
- Yamaguchi University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1. Following serous comlicating diseases, except for chronic hepatitis and liver cirrhosis: a) Renal failure with blood or peritoneal dialysis b) Heart failure >/= NYHA class III, serious ischemic herat disease, and serious arhythmia c) uncontrolled hypertension d) brain tumors 2. Past or present history of malignant tumors except for HCC 3. Past history of allergy in iodine or contrast agent 4. Inadequate patient judged by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship between side effects and gene polymorphism
- Secondary Outcome Measures
Name Time Method Relationship between prognosis and gene polymorphism